{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T16:14:04Z","timestamp":1785600844460,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Hubro Therapeutics AS"},{"name":"The Research Council of Norway","award":["Project No.: 321590"],"award-info":[{"award-number":["Project No.: 321590"]}]},{"name":"The Research Council of Norway","award":["Project No.: 321590"],"award-info":[{"award-number":["Project No.: 321590"]}]},{"name":"The Research Council of Norway","award":["Project No.: 321590"],"award-info":[{"award-number":["Project No.: 321590"]}]},{"name":"The Research Council of Norway","award":["Project No.: 321590"],"award-info":[{"award-number":["Project No.: 321590"]}]},{"name":"The Research Council of Norway","award":["Project No.: 321590"],"award-info":[{"award-number":["Project No.: 321590"]}]},{"name":"The Research Council of Norway","award":["Project No.: 321590"],"award-info":[{"award-number":["Project No.: 321590"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-03969-6","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T08:38:27Z","timestamp":1740472707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Generation of frameshift-mutated TGF\u03b2R2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1\/GM-CSF in a phase 1 study"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6147-3536","authenticated-orcid":false,"given":"Else Marit","family":"Inderberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6683-7450","authenticated-orcid":false,"given":"Nand","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2030-1778","authenticated-orcid":false,"given":"Robert","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0352-5307","authenticated-orcid":false,"given":"Sarah","family":"Arbe-Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3856-5775","authenticated-orcid":false,"given":"Henrik K.","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit","family":"lversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedvig Vidarsdotter","family":"Juul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9987-6764","authenticated-orcid":false,"given":"Jon Amund","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karianne Risberg","family":"Handeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"issue":"4","key":"3969_CR1","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/bjc.2015.281","volume":"113","author":"M Pinheiro","year":"2015","unstructured":"Pinheiro M, Pinto C, Peixoto A et al (2015) Target gene mutational pattern in Lynch syndrome colorectal carcinomas according to tumour location and germline mutation. Br J Cancer 113(4):686\u2013692. https:\/\/doi.org\/10.1038\/bjc.2015.281","journal-title":"Br J Cancer"},{"issue":"48","key":"3969_CR2","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.3748\/wjg.v24.i48.5418","volume":"24","author":"S Wagner","year":"2018","unstructured":"Wagner S, Mullins CS, Linnebacher M (2018) Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens. World J Gastroenterol 24(48):5418\u20135432. https:\/\/doi.org\/10.3748\/wjg.v24.i48.5418","journal-title":"World J Gastroenterol"},{"issue":"5","key":"3969_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1115943","volume":"5","author":"P Maby","year":"2016","unstructured":"Maby P, Galon J, Latouche JB (2016) Frameshift mutations, neoantigens and tumor-specific CD8(+) T cells in microsatellite unstable colorectal cancers. Oncoimmunology 5(5):e1115943. https:\/\/doi.org\/10.1080\/2162402X.2015.1115943","journal-title":"Oncoimmunology"},{"issue":"3","key":"3969_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.trecan.2016.02.004","volume":"2","author":"M Kloor","year":"2016","unstructured":"Kloor M, von Knebel DM (2016) The immune biology of microsatellite-unstable cancer. Trends Cancer 2(3):121\u2013133. https:\/\/doi.org\/10.1016\/j.trecan.2016.02.004","journal-title":"Trends Cancer"},{"issue":"23","key":"3969_CR5","doi-asserted-by":"publisher","first-page":"13255","DOI":"10.1073\/pnas.231326898","volume":"98","author":"I Saeterdal","year":"2001","unstructured":"Saeterdal I, Bjorheim J, Lislerud K et al (2001) Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 98(23):13255\u201313260. https:\/\/doi.org\/10.1073\/pnas.231326898","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3969_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ijc.1298","volume":"93","author":"M Linnebacher","year":"2001","unstructured":"Linnebacher M et al (2001) Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer 93(1):6\u201311. https:\/\/doi.org\/10.1002\/ijc.1298. (PMID: 11391614)","journal-title":"Int J Cancer"},{"issue":"10","key":"3969_CR7","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41416-019-0599-y","volume":"121","author":"IH Sahin","year":"2019","unstructured":"Sahin IH, Akce M, Alese O et al (2019) Immune checkpoint inhibitors for the treatment of MSI-H\/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer 121(10):809\u2013818. https:\/\/doi.org\/10.1038\/s41416-019-0599-y","journal-title":"Br J Cancer"},{"issue":"22","key":"3969_CR8","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1158\/1078-0432.CCR-22-1927","volume":"28","author":"P Hillemanns","year":"2022","unstructured":"Hillemanns P, Denecke A, Woelber L, B\u00f6hmer G, Jentschke M, Schjetne KW, Slot KMH, Fredriksen AB (2022) A therapeutic antigen-presenting cell-targeting DNA vaccine VB10.16 in HPV16-positive high-grade cervical intraepithelial neoplasia: results from a phase I\/IIa Trial. Clin Cancer Res 28(22):4885","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3969_CR9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41416-020-0752-7","volume":"122","author":"DH Palmer","year":"2020","unstructured":"Palmer DH, Valle JW, Ma YT, Faluyi O, Neoptolemos JP, Gjertsen TJ, Iversen B, Eriksen JA, M\u00f8ller AS, Aksnes AK, Miller RM, Dueland S (2020) TG01\/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1\/2 trial. Br J Cancer 122(7):971\u2013977. https:\/\/doi.org\/10.1038\/s41416-020-0752-7","journal-title":"Br J Cancer"},{"issue":"12","key":"3969_CR10","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1038\/s41591-021-01544-x","volume":"27","author":"JW Kjeldsen","year":"2021","unstructured":"Kjeldsen JW et al (2021) A phase 1\/2 trial of an immune-modulatory vaccine against IDO\/PD-L1 in combination with nivolumab in metastatic melanoma. Nat Med 27(12):2212\u20132223. https:\/\/doi.org\/10.1038\/s41591-021-01544-x. (Epub 2021 Dec)","journal-title":"Nat Med"},{"key":"3969_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113973","volume":"202","author":"VD Haakensen","year":"2024","unstructured":"Haakensen VD, Ojlert AK, Thunold S et al (2024) UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma\u2014a phase II randomised trial. Eur J Cancer 202:113973","journal-title":"Eur J Cancer"},{"key":"3969_CR12","doi-asserted-by":"publisher","first-page":"100022","DOI":"10.1074\/mcp.R120.002309","volume":"20","author":"A Nelde","year":"2021","unstructured":"Nelde A, Rammensee HG, Walz JS (2021) The peptide vaccine of the future. Mol Cell Proteom 20:100022","journal-title":"Mol Cell Proteom"},{"issue":"4","key":"3969_CR13","first-page":"1347","volume":"6","author":"ML Disis","year":"2000","unstructured":"Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL (2000) Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2\/neu peptide immunization. Clin Cancer Res 6(4):1347\u20131350","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3969_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/ijc.1205","volume":"92","author":"MK Gjertsen","year":"2001","unstructured":"Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, S\u00f8reide O, Eriksen JA, M\u00f8ller M, Baksaas I, Lothe RA, Saeterdal I, Gaudernack G (2001) Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92(3):441\u2013450. https:\/\/doi.org\/10.1002\/ijc.1205. (PMID: 11291084)","journal-title":"Int J Cancer"},{"issue":"23","key":"3969_CR15","doi-asserted-by":"publisher","first-page":"13255","DOI":"10.1073\/pnas.231326898","volume":"98","author":"I S\u00e6terdal","year":"2001","unstructured":"S\u00e6terdal I, Bj\u00f8rheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, M\u00f8ller M, Lindblom A, Gaudernack G (2001) Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. PNAS 98(23):13255\u201313260","journal-title":"PNAS"},{"key":"3969_CR16","first-page":"469","volume":"50","author":"I S\u00e6terdal","year":"2002","unstructured":"S\u00e6terdal I, Gjertsen MK, Straten P, Eriksen JA, Gaudernack G (2002) A TGF\u03b2RII frameshift-mutation-derived CTL epitope recognized HLA-A2-restricted CD8+ T cells. Cancer Immunol Immunother 50:469\u2013476","journal-title":"Cancer Immunol Immunother"},{"key":"3969_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ijc.1298","volume":"93","author":"M Linnebacher","year":"2001","unstructured":"Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, Von Knebel Doeberitz M (2001) Frameshift peptide-derived T-cell epitopes: A source of novel tumor-specific antigens. Int J Cancer 93:6\u201311","journal-title":"Int J Cancer"},{"key":"3969_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.757804","volume":"12","author":"V Roudko","year":"2021","unstructured":"Roudko V, Cimen Bozkus C, Greenbaum B, Lucas A, Samstein R, Bhardwaj N (2021) Lynch syndrome and MSI-H cancers: from mechanisms to \u201coff-the-shelf\u201d cancer vaccines. Front Immunol 12:757804. https:\/\/doi.org\/10.3389\/fimmu.2021.757804","journal-title":"Front Immunol"},{"issue":"10","key":"3969_CR19","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3810","volume":"11","author":"RJ Akhurst","year":"2012","unstructured":"Akhurst RJ, Hata A (2012) Targeting the TGFbeta signalling pathway in disease. Nat Rev Drug Discov 11(10):790\u2013811. https:\/\/doi.org\/10.1038\/nrd3810","journal-title":"Nat Rev Drug Discov"},{"issue":"5215","key":"3969_CR20","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1126\/science.7761852","volume":"268","author":"S Markowitz","year":"1995","unstructured":"Markowitz S, Wang J, Myeroff L et al (1995) Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268(5215):1336\u20131338. https:\/\/doi.org\/10.1126\/science.7761852","journal-title":"Science"},{"issue":"4","key":"3969_CR21","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3892\/ijo.2019.4859","volume":"55","author":"F Fricke","year":"2019","unstructured":"Fricke F, Mussack V, Buschmann D et al (2019) TGFBR2-dependent alterations of microRNA profiles in extracellular vesicles and parental colorectal cancer cells. Int J Oncol 55(4):925\u2013937. https:\/\/doi.org\/10.3892\/ijo.2019.4859","journal-title":"Int J Oncol"},{"issue":"19","key":"3969_CR22","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1002\/cncr.26574","volume":"118","author":"EA Mittendorf","year":"2012","unstructured":"Mittendorf EA, Clifton GT, Holmes JP et al (2012) Clinical trial results of HER-2\/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients. Cancer 118(19):2594\u20132602","journal-title":"Cancer"},{"issue":"16","key":"3969_CR23","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1158\/1078-0432.CCR-23-0416","volume":"29","author":"EB Ellingsen","year":"2023","unstructured":"Ellingsen EB, O\u2019Day S, Mezheyeuski A et al (2023) Clinical activity of combined telomerase vaccination and pembrolizumab in advanced melanoma: results from a phase I trial. Clin Cancer Res 29(16):3026\u20133036","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3969_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3390\/biomedicines11010177","volume":"11","author":"MT Chu","year":"2023","unstructured":"Chu MT, Chang WC, Pao SC, Hung SI (2023) Delayed drug hypersensitivity reactions: molecular recognition, genetic susceptibility, and immune mediators. Biomedicines. 11(1):177. https:\/\/doi.org\/10.3390\/biomedicines11010177","journal-title":"Biomedicines."},{"issue":"9","key":"3969_CR25","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1128\/CVI.00004-07","volume":"14","author":"C Barbey","year":"2007","unstructured":"Barbey C, Pradervand E, Barbier N et al (2007) Ex vivo monitoring of antigen-specific CD4+ T cells after recall immunization with tetanus toxoid. Clin Vaccine Immunol 14(9):1108\u20131116","journal-title":"Clin Vaccine Immunol"},{"key":"3969_CR26","doi-asserted-by":"publisher","first-page":"112907","DOI":"10.1016\/j.jim.2020.112907","volume":"487","author":"D Di Blasi","year":"2020","unstructured":"Di Blasi D, Claessen I, Turksma AW et al (2020) Guidelines for analysis of low-frequency antigen-specific T cell results: Dye-based proliferation assay vs 3H-thymidine incorporation. J Immunol Methods 487:112907","journal-title":"J Immunol Methods"},{"issue":"5","key":"3969_CR27","doi-asserted-by":"publisher","first-page":"e0178544","DOI":"10.1371\/journal.pone.0178544","volume":"12","author":"HS Schultz","year":"2017","unstructured":"Schultz HS, Reedtz-Runge SL, B\u00e4ckstr\u00f6m BT et al (2017) Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in helathy donors using a novel T cell:PBMC assay. PLoS ONE 12(5):e0178544","journal-title":"PLoS ONE"},{"issue":"12","key":"3969_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663865","volume":"11","author":"E Aamdal","year":"2021","unstructured":"Aamdal E, Inderberg EM, Ellingsen EB et al (2021) Combining a universal telomerase based cancer vaccine with ipilimumab in patients with metastatic melanoma \u2013 five-year follow up of a phase I\/Iia Trial. Front Immunol 11(12):663865","journal-title":"Front Immunol"},{"issue":"1","key":"3969_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1365-2249.2010.04272.x","volume":"163","author":"R Mallone","year":"2011","unstructured":"Mallone R, Mannering SI, Brooks-Worrell BM et al (2011) Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin Exp Immunol 163(1):33\u201349","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"3969_CR30","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jid.2015.11.020","volume":"136","author":"GA Romar","year":"2016","unstructured":"Romar GA et al (2016) Research techniques made simple: techniques to assess cell proliferation. J Invest Dermatol 136(1):e1\u2013e7. https:\/\/doi.org\/10.1016\/j.jid.2015.11.020","journal-title":"J Invest Dermatol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03969-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-03969-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-03969-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T05:16:25Z","timestamp":1743052585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-03969-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["3969"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-03969-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5418259\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-5418259\/v2","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"8 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NS is an employee of Quotient Sciences which was contracted by Hubro Therapeutics AS to conduct the study. RMM, SA-B, HKE, BI, JAE and KRH were employed by study sponsor. EMI and HVJ are employees of Translational Research Unit, Section for Cellular Therapy, Department of Oncology, Oslo University Hospital\u2014Radiumhospitalet, Oslo, Norway. The authors have no relevant financial or non-financial interests to disclose. The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the UK Medicines and Healthcare products Regulatory Agency and the protocol approved by the London \u2013 West London & Gene Therapy Advisory Committee Research Ethics Committee, the Norwegian National Research Ethics Committee and written informed consent was obtained from all subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they consent for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"115"}}